Australia's most trusted
source of pharma news
Thursday, 02 May 2024
Posted 18 April 2024 AM
Sanofi has contracted Melbourne-based IDT Australia to manufacture its investigational mRNA-based vaccines in a new multimillion-dollar deal.
The Master Service Agreement announced earlier this week is a major step forward for Sanofi in bringing the Translational Science Hub (TSH) to life as it allows the French pharmaceutical giant flexibility to choose services from IDT and for follow-on work packages.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.